Balchem (BCPC) Stock Forecast, Price Target & Predictions
BCPC Stock Forecast
Balchem stock forecast is as follows: an average price target of $152.00 (represents a -12.26% downside from BCPC’s last price of $173.24) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
BCPC Price Target
The average price target for Balchem (BCPC) is $152.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $152.00 to $152.00. This represents a potential -12.26% downside from BCPC's last price of $173.24.
BCPC Analyst Ratings
According to 2 Wall Street analysts, Balchem's rating consensus is 'Buy'. The analyst rating breakdown for BCPC stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Balchem Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 02, 2022 | - | H.C. Wainwright | $152.00 | $123.20 | 23.38% | -12.26% |
The latest Balchem stock forecast, released on May 02, 2022 by H.C. Wainwright company, set a price target of $152.00, which represents a 23.38% increase from the stock price at the time of the forecast ($123.20), and a -12.26% decrease from BCPC last price ($173.24).
Balchem Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $173.24 | $173.24 | $173.24 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Balchem stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Balchem's last price of $173.24. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| May 06, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Oct 30, 2023 | UBS | Buy | Buy | Hold |
Balchem's last stock rating was published by H.C. Wainwright on May 06, 2024. The company gave BCPC a "Buy" rating, the same as its previous rate.
Balchem Financial Forecast
Balchem Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $229.95M | $231.25M | $232.54M | $232.53M | $244.27M | - | $228.87M | $213.13M | $197.87M | $202.37M | $185.66M | $180.71M | $175.14M | $173.35M | $174.44M | $166.53M | $158.59M |
| Avg Forecast | $294.86M | $288.13M | $281.56M | $275.13M | $267.14M | $265.07M | $261.10M | $253.85M | $244.84M | $241.45M | $239.68M | $232.46M | $234.66M | $237.08M | $244.87M | $233.52M | $241.47M | $239.62M | $223.53M | $207.69M | $198.17M | $196.13M | $185.44M | $181.59M | $175.33M | $169.55M | $161.35M | $169.87M | $165.55M | $167.43M |
| High Forecast | $300.29M | $293.44M | $286.75M | $280.20M | $272.06M | $269.95M | $265.91M | $258.52M | $249.35M | $244.96M | $244.10M | $236.74M | $238.64M | $242.50M | $249.38M | $237.83M | $245.92M | $244.04M | $223.53M | $209.17M | $199.58M | $197.53M | $186.77M | $182.88M | $176.58M | $170.76M | $162.50M | $171.08M | $166.73M | $168.62M |
| Low Forecast | $291.68M | $285.03M | $278.52M | $272.17M | $264.26M | $262.21M | $258.29M | $251.11M | $242.21M | $237.93M | $237.10M | $229.96M | $230.68M | $234.30M | $242.23M | $231.01M | $238.87M | $237.04M | $223.53M | $206.21M | $196.76M | $194.73M | $184.12M | $180.30M | $174.08M | $168.34M | $160.20M | $168.66M | $164.37M | $166.23M |
| # Analysts | 1 | 1 | 1 | 1 | - | - | - | - | 1 | 2 | 1 | 1 | 2 | 3 | 1 | 1 | 1 | 1 | - | - | 2 | 2 | 2 | 9 | 10 | 16 | 9 | 10 | 8 | 8 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.97% | 0.94% | 1.00% | 0.96% | 1.02% | - | 1.10% | 1.08% | 1.01% | 1.09% | 1.02% | 1.03% | 1.03% | 1.07% | 1.03% | 1.01% | 0.95% |
Balchem's average Quarter revenue forecast for Dec 23 based on 2 analysts is $234.66M, with a low forecast of $230.68M, and a high forecast of $238.64M. BCPC's average Quarter revenue forecast represents a 2.05% increase compared to the company's last Quarter revenue of $229.95M (Sep 23).
Balchem EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | - | - | - | - | 1 | 2 | 1 | 1 | 2 | 3 | 1 | 1 | 1 | 1 | - | - | 2 | 2 | 2 | 9 | 10 | 16 | 9 | 10 | 8 | 8 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $43.61M | $42.84M | $48.05M | $33.30M | $48.82M | - | $50.10M | $45.40M | $44.80M | $42.73M | $43.07M | $41.81M | $41.91M | $39.68M | $38.73M | $35.95M | $37.86M |
| Avg Forecast | $67.42M | $65.88M | $64.38M | $62.91M | $61.08M | $60.61M | $59.70M | $58.04M | $55.99M | $55.21M | $54.81M | $45.10M | $53.66M | $54.21M | $55.99M | $41.00M | $55.21M | $48.18M | $51.11M | $37.27M | $44.80M | $43.80M | $42.40M | $42.06M | $40.78M | $34.13M | $21.04M | $26.03M | $34.24M | $34.28M |
| High Forecast | $68.66M | $67.10M | $65.57M | $64.07M | $62.21M | $61.73M | $60.80M | $59.11M | $57.02M | $56.01M | $55.82M | $54.12M | $54.57M | $55.45M | $57.02M | $49.20M | $56.23M | $57.82M | $51.11M | $44.73M | $53.76M | $52.57M | $42.71M | $50.47M | $48.93M | $40.96M | $25.25M | $31.24M | $41.09M | $41.14M |
| Low Forecast | $66.70M | $65.17M | $63.69M | $62.23M | $60.43M | $59.96M | $59.06M | $57.42M | $55.38M | $54.41M | $54.22M | $36.08M | $52.75M | $53.57M | $55.39M | $32.80M | $54.62M | $38.55M | $51.11M | $29.82M | $35.84M | $35.04M | $42.10M | $33.65M | $32.62M | $27.30M | $16.83M | $20.83M | $27.39M | $27.42M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.80% | 0.77% | 1.17% | 0.60% | 1.01% | - | 1.34% | 1.01% | 1.02% | 1.01% | 1.02% | 1.03% | 1.23% | 1.89% | 1.49% | 1.05% | 1.10% |
2 analysts predict BCPC's average Quarter EBITDA for Dec 23 to be $53.66M, with a high of $54.57M and a low of $52.75M. This is 23.03% upper than Balchem's previous annual EBITDA (Sep 23) of $43.61M.
Balchem Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | - | - | - | - | 1 | 2 | 1 | 1 | 2 | 3 | 1 | 1 | 1 | 1 | - | - | 2 | 2 | 2 | 9 | 10 | 16 | 9 | 10 | 8 | 8 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $29.07M | $30.11M | $22.71M | $21.41M | $25.25M | - | $28.93M | $24.95M | $25.01M | $22.73M | $23.41M | $22.16M | $21.57M | $21.13M | $19.77M | $20.38M | $20.68M |
| Avg Forecast | $41.79M | $42.44M | $42.44M | $41.79M | $40.81M | $40.48M | $39.67M | $38.53M | $37.38M | $36.40M | $33.79M | $26.04M | $30.36M | $31.67M | $27.43M | $23.67M | $26.12M | $26.90M | $30.67M | $21.52M | $24.62M | $24.46M | $26.63M | $22.86M | $21.61M | $17.56M | $11.20M | $13.29M | $19.41M | $18.72M |
| High Forecast | $42.79M | $43.46M | $43.46M | $42.79M | $41.79M | $41.45M | $40.62M | $39.45M | $38.28M | $39.58M | $34.60M | $31.25M | $31.06M | $34.28M | $28.08M | $28.41M | $26.75M | $32.28M | $30.67M | $25.83M | $29.54M | $29.35M | $26.88M | $27.43M | $25.94M | $21.08M | $13.44M | $15.94M | $23.29M | $22.46M |
| Low Forecast | $41.21M | $41.85M | $41.85M | $41.21M | $40.24M | $39.92M | $39.11M | $37.99M | $36.86M | $33.22M | $33.32M | $20.83M | $29.67M | $29.06M | $27.04M | $18.94M | $25.75M | $21.52M | $30.67M | $17.22M | $19.69M | $19.57M | $26.38M | $18.29M | $17.29M | $14.05M | $8.96M | $10.63M | $15.53M | $14.98M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.92% | 1.10% | 0.96% | 0.82% | 0.94% | - | 1.34% | 1.01% | 1.02% | 0.85% | 1.02% | 1.03% | 1.23% | 1.89% | 1.49% | 1.05% | 1.10% |
Balchem's average Quarter net income forecast for Dec 23 is $30.36M, with a range of $29.67M to $31.06M. BCPC's average Quarter net income forecast represents a 4.43% increase compared to the company's last Quarter net income of $29.07M (Sep 23).
Balchem SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | - | - | - | - | 1 | 2 | 1 | 1 | 2 | 3 | 1 | 1 | 1 | 1 | - | - | 2 | 2 | 2 | 9 | 10 | 16 | 9 | 10 | 8 | 8 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $29.06M | $30.72M | $35.31M | $32.29M | $31.81M | - | $29.94M | - | $25.27M | $25.95M | $25.40M | $25.52M | $24.65M | $25.89M | $26.35M | $27.77M | $25.28M |
| Avg Forecast | $39.71M | $38.81M | $37.92M | $37.06M | $35.98M | $35.70M | $35.17M | $34.19M | $32.98M | $32.52M | $32.28M | $26.95M | $31.61M | $31.93M | $32.98M | $24.50M | $32.52M | $27.17M | $30.11M | $22.27M | $26.69M | $24.70M | $24.98M | $24.81M | $24.89M | $20.07M | $13.73M | $17.71M | $26.45M | $22.89M |
| High Forecast | $40.45M | $39.52M | $38.62M | $37.74M | $36.64M | $36.36M | $35.81M | $34.82M | $33.58M | $32.99M | $32.88M | $32.34M | $32.14M | $32.66M | $33.59M | $29.40M | $33.12M | $32.61M | $30.11M | $26.73M | $26.88M | $29.64M | $25.15M | $29.77M | $29.87M | $24.08M | $16.48M | $21.26M | $31.74M | $27.47M |
| Low Forecast | $39.29M | $38.39M | $37.51M | $36.66M | $35.59M | $35.32M | $34.79M | $33.82M | $32.62M | $32.05M | $31.93M | $21.56M | $31.07M | $31.56M | $32.62M | $19.60M | $32.17M | $21.74M | $30.11M | $17.82M | $26.50M | $19.76M | $24.80M | $19.84M | $19.91M | $16.06M | $10.99M | $14.17M | $21.16M | $18.31M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.91% | 0.93% | 1.44% | 0.99% | 1.17% | - | 1.34% | - | 1.02% | 1.04% | 1.02% | 1.03% | 1.23% | 1.89% | 1.49% | 1.05% | 1.10% |
Balchem's average Quarter SG&A projection for Dec 23 is $31.61M, based on 2 Wall Street analysts, with a range of $31.07M to $32.14M. The forecast indicates a 8.75% rise compared to BCPC last annual SG&A of $29.06M (Sep 23).
Balchem EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | - | - | - | - | 1 | 2 | 1 | 1 | 2 | 3 | 1 | 1 | 1 | 1 | - | - | 2 | 2 | 2 | 9 | 10 | 16 | 9 | 10 | 8 | 8 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $0.91 | $0.94 | $0.71 | $0.67 | $0.79 | - | $0.90 | $0.77 | $0.78 | $0.70 | $0.73 | $0.68 | $0.67 | $0.66 | $0.62 | $0.63 | $0.64 |
| Avg Forecast | $1.28 | $1.30 | $1.30 | $1.28 | $1.25 | $1.24 | $1.22 | $1.18 | $1.15 | $1.11 | $1.03 | $0.98 | $0.93 | $0.97 | $0.84 | $0.72 | $0.80 | $0.94 | $0.94 | $0.82 | $0.78 | $0.84 | $0.82 | $0.79 | $0.69 | $0.66 | $0.56 | $0.62 | $0.69 | $0.66 |
| High Forecast | $1.31 | $1.33 | $1.33 | $1.31 | $1.28 | $1.27 | $1.24 | $1.21 | $1.17 | $1.21 | $1.06 | $1.00 | $0.95 | $1.05 | $0.86 | $0.74 | $0.82 | $0.96 | $0.94 | $0.83 | $0.79 | $0.85 | $0.83 | $0.80 | $0.69 | $0.67 | $0.56 | $0.63 | $0.70 | $0.67 |
| Low Forecast | $1.26 | $1.28 | $1.28 | $1.26 | $1.23 | $1.22 | $1.20 | $1.16 | $1.13 | $1.02 | $1.02 | $0.97 | $0.91 | $0.89 | $0.83 | $0.71 | $0.79 | $0.92 | $0.94 | $0.81 | $0.77 | $0.83 | $0.81 | $0.78 | $0.68 | $0.66 | $0.55 | $0.61 | $0.68 | $0.65 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.94% | 1.12% | 0.99% | 0.84% | 0.84% | - | 1.10% | 0.99% | 0.93% | 0.86% | 0.92% | 1.00% | 1.01% | 1.19% | 1.00% | 0.92% | 0.97% |
According to 2 Wall Street analysts, Balchem's projected average Quarter EPS for Dec 23 is $0.93, with a low estimate of $0.91 and a high estimate of $0.95. This represents a 2.20% increase compared to BCPC previous annual EPS of $0.91 (Sep 23).
Balchem Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ASH | Ashland | $87.19 | $117.30 | 34.53% | Buy |
| MTX | Minerals | $71.61 | $90.00 | 25.68% | Buy |
| KWR | Quaker Chemical | $169.26 | $197.50 | 16.68% | Buy |
| SXT | Sensient | $76.67 | $85.00 | 10.86% | - |
| FUL | H.B. Fuller Company | $81.66 | $85.60 | 4.82% | Buy |
| AXTA | Axalta Coating Systems | $35.70 | $36.73 | 2.89% | Buy |
| CBT | Cabot | $107.42 | $99.50 | -7.37% | Hold |
| BCPC | Balchem | $173.24 | $152.00 | -12.26% | Buy |
BCPC Forecast FAQ
Is Balchem a good buy?
Yes, according to 2 Wall Street analysts, Balchem (BCPC) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of BCPC's total ratings.
What is BCPC's price target?
Balchem (BCPC) average price target is $152 with a range of $152 to $152, implying a -12.26% from its last price of $173.24. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Balchem stock go up soon?
According to Wall Street analysts' prediction for BCPC stock, the company can go down by -12.26% (from the last price of $173.24 to the average price target of $152), down by -12.26% based on the highest stock price target, and down by -12.26% based on the lowest stock price target.
Can Balchem stock reach $300?
BCPC's average twelve months analyst stock price target of $152 does not support the claim that Balchem can reach $300 in the near future.
What are Balchem's analysts' financial forecasts?
Balchem's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $1.05B (high $1.07B, low $1.04B), average EBITDA is $239.44M (high $243.85M, low $236.86M), average net income is $159.49M (high $163.31M, low $157.26M), average SG&A $141.04M (high $143.64M, low $139.52M), and average EPS is $4.88 (high $5, low $4.82). BCPC's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $1.14B (high $1.16B, low $1.13B), average EBITDA is $260.6M (high $265.4M, low $257.79M), average net income is $168.47M (high $172.51M, low $166.11M), average SG&A $153.5M (high $156.33M, low $151.84M), and average EPS is $5.16 (high $5.28, low $5.09).
Did the BCPC's actual financial results beat the analysts' financial forecasts?
Based on Balchem's last annual report (Dec 2022), the company's revenue was $942.36M, beating the average analysts forecast of $912.31M by 3.29%. Apple's EBITDA was $197.03M, beating the average prediction of $191.78M by 2.74%. The company's net income was $105.37M, beating the average estimation of $105.21M by 0.15%. Apple's SG&A was $123.07M, beating the average forecast of $112.07M by 9.82%. Lastly, the company's EPS was $3.29, missing the average prediction of $3.49 by -5.87%. In terms of the last quarterly report (Sep 2023), Balchem's revenue was $229.95M, missing the average analysts' forecast of $237.08M by -3.01%. The company's EBITDA was $43.61M, missing the average prediction of $54.21M by -19.55%. Balchem's net income was $29.08M, missing the average estimation of $31.67M by -8.19%. The company's SG&A was $29.06M, missing the average forecast of $31.93M by -8.98%. Lastly, the company's EPS was $0.91, missing the average prediction of $0.97 by -6.19%